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In vivo glucose metabolism and glutamate 
levels in mGluR5 knockout mice: a multimodal 
neuroimaging study using  [18F]FDG microPET 
and MRS
Yo‑Han Joo1, Yun‑Kwan Kim1, In‑Gyu Choi1, Hyeon‑Jin Kim2,3, Young‑Don Son1,4,5, Hang‑Keun Kim1,4,5, 
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Abstract 
Background: Perturbed functional coupling between the metabotropic glutamate receptor‑5 (mGluR5) and 
N‑methyl‑d‑aspartate (NMDA) receptor‑mediated excitatory glutamatergic neurotransmission may contribute to 
the pathophysiology of psychiatric disorders such as schizophrenia. We aimed to establish the functional interaction 
between mGluR5 and NMDA receptors in brain of mice with genetic ablation of the mGluR5.
Methods: We first measured the brain glutamate levels with magnetic resonance spectroscopy (MRS) in mGluR5 
knockout (KO) and wild‑type (WT) mice. Then, we assessed brain glucose metabolism with  [18F]fluorodeoxyglucose 
 ([18F]FDG) positron emission tomography before and after the acute administration of an NMDA antagonist, MK‑801 
(0.5 mg/kg), in the same mGluR5 KO and WT mice.
Results: Between‑group comparisons showed no significant differences in  [18F]FDG standardized uptake values 
(SUVs) in brain of mGluR5 KO and WT mice at baseline, but widespread reductions in mGluR5 KO mice compared to 
WT mice after MK‑801 administration (p < 0.05). The baseline glutamate levels did not differ significantly between the 
two groups. However, there were significant negative correlations between baseline prefrontal glutamate levels and 
regional  [18F]FDG SUVs in mGluR5 KO mice (p < 0.05), but no such correlations in WT mice. Fisher’s Z‑transformation 
analysis revealed significant between‑group differences in these correlations (p < 0.05).
Conclusions: This is the first multimodal neuroimaging study in mGluR5 KO mice and the first report on the associa‑
tion between cerebral glucose metabolism and glutamate levels in living rodents. The results indicate that mGluR5 KO 
mice respond to NMDA antagonism with reduced cerebral glucose metabolism, suggesting that mGluR5 transmis‑
sion normally moderates the net effects of NMDA receptor antagonism on neuronal activity. The negative correlation 
between glutamate levels and glucose metabolism in mGluR5 KO mice at baseline may suggest an unmasking of an 
inhibitory component of the glutamatergic regulation of neuronal energy metabolism.
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Introduction
Glutamate is the most abundant excitatory neurotrans-
mitter in the brain and is consequently a major driver for 
neuronal energy expenditure. The energy budget of brain 
is uniquely dependent on oxidative phosphorylation of 
pyruvate derived from glycolysis [1, 2]. Nonetheless, 
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neuronal energy metabolism can be assessed in  vivo by 
using positron emission tomography (PET) with the gly-
colysis tracer  [18F]fluorodeoxyglucose  ([18F]FDG), which 
gives an index of the glucose metabolism that is coupled 
to glutamatergic neuronal activity [3, 4]. Glutamatergic 
signaling plays critical roles in synaptic plasticity and 
the regulation of cognitive, behavioral, and affective pro-
cesses [5–7]. As such, dysfunction of glutamatergic neu-
rotransmission is implicated in the pathophysiology of 
major psychiatric disorders such as schizophrenia and 
depressive disorders [8, 9] and is also involved in excito-
toxic and neurodegenerative diseases [10, 11].
The glutamate receptors in brain belong to two 
major classes, the ionotropic ligand-gated ion chan-
nels such as N-methyl-d-aspartate (NMDA) receptors 
and a diverse family of metabotropic glutamate recep-
tors (mGluR) linked to intracellular second messenger 
systems. Among the latter group, the type 5 metabo-
tropic receptor (mGluR5) is an important player in glu-
tamatergic signaling [12–14]. Previous studies reported 
that mGluR5 is functionally linked to NMDA receptors 
via scaffold proteins of the post-synaptic density (PSD), 
such as Homer, Shank, and PSD-95 [15, 16]. Increasing 
evidence indicates that the activation of NMDA recep-
tors is potentiated by concomitant mGluR5-mediated 
signaling [16, 17] and that stimulation of NMDA recep-
tors reciprocally enhances mGluR5 function [18, 19]. 
The synergistic action of glutamate signaling at mGluR5/
NMDA receptors [20, 21] is further attested by obser-
vations that genetic ablation of mGluR5 interfered with 
NMDA receptor-mediated long-term potentiation in the 
hippocampus [22, 23]. In addition, while pharmacologi-
cal antagonism of mGluR5 did not provoke deficits in the 
prepulse inhibition (PPI) of the acoustic startle response 
in rodents, mGluR5 antagonism significantly potenti-
ated the PPI disruption induced by the NMDA receptor 
antagonist, MK-801 [24], suggesting a mGluR5/NMDA 
synergism in this important behavioral endophenotype 
of schizophrenia. Furthermore, recent rodent studies 
associate dysregulation of mGluR5/NMDA signaling 
with a range of neurocognitive deficits, which are among 
the core features of schizophrenia [25, 26]. Thus, the fur-
ther investigation of mGluR5/NMDA synergism may 
shed new light on the underlying characteristics of glu-
tamatergic dysfunction in psychiatric disorders such as 
schizophrenia.
The mGluR5 knockout (KO) mouse model enables the 
investigation of behavioral phenotypes associated with 
metabotropic glutamatergic signaling abnormalities 
[20, 27]. However, there has been no direct evaluation 
of mGluR5/NMDA synergism based on observations of 
brain energy metabolism and glutamate levels in brain 
of mice with genetic ablation of the mGluR5. Thus, 
we undertook this in  vivo multimodal imaging study 
with groups of wild-type (WT) and mGluR5 KO mice 
to examine the effects of mGluR5 KO on brain glucose 
metabolism measured with  [18F]FDG PET and gluta-
mate levels measured with magnetic resonance spectros-
copy (MRS). To test the reciprocal interaction between 
mGluR5 and NMDA receptors, we measured brain glu-
cose metabolism before and after acute administration of 
the NMDA antagonist MK-801 in WT and KO mice.
Materials and methods
Animals
Mice heterozygous for mGluR5 (B6.129-Grm5tm1Rod/J, 
stock #003558) in C57BL/6J background were purchased 
from Jackson Laboratory (Bar Harbor, Maine). Three 
pairs of the first-generation mGluR5 heterozygous mice 
were bred to obtain 11 mGluR5 KO (Grm5 −/−, six F3 
and five F4) and 10 WT (Grm5 +/+, six F3 and four F4) 
mice. The genotype of each mouse was identified by poly-
merase chain reaction (PCR) analysis (Macrogen, South 
Korea). The mice had ad libitum access to food and water 
and were separately housed in single-sex cages with a 
12-h light–dark cycle. All experiments were approved 
by the Institutional Animal Care and Use Committee 
(IACUC) of Gachon University (GU-NRI-17-001) and 
Seoul National University College of Medicine (SNU-
16-0189-S1A1) and were carried out in strict accordance 
with the recommendations in the Guide for the Care 
and Use of Laboratory Animals 8th edition, National 
Research Council (2011).
[18F]FDG microPET
The  [18F]FDG microPET study was performed at 
Gachon University College of Medicine. Prior to PET 
scans, each mouse was deprived of food for at least 12 h 
and then received a bolus tail vein injection of 
4.2 ± 0.6 MBq  [18F]FDG in approximately 200 µL. Base-
line PET scans were followed 2  weeks later by second 
fasting PET scans with acute administration of MK-801 
(0.5 mg/kg) at 30 min before  [18F]FDG injection. Imme-
diately after tracer injection, mice were placed in a hold-
ing cage for 30 min of  [18F]FDG uptake and then rapidly 
anesthetized with 2.5% isoflurane in 80% oxygen. Within 
a minute of induction, mice were placed in the aperture 
of the Focus 120 microPET (Concorde Microsystems, 
Knoxville, TN, USA) with continued inhalation anesthe-
sia during the recording of a single emission frame last-
ing 30 min. After attenuation correction, the static PET 
emission images were reconstructed using a three-
dimensional ordered subset expectation maximization 
(3D-OSEM) algorithm. The voxel size was 
0.216 × 0.216  mm and of 0.796  mm thickness. The 
whole brain PET image of each mouse was segmented 
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from the original PET images by manual editing of the 
extracerebral voxels using the PMOD software (PMOD 
version 3.9, PMOD Technologies Ltd., Zurich, Switzer-
land). The images were then co-registered and spatially 
normalized to a  [18F]FDG PET mouse brain template 
[28] using nine parameters with statistical parametric 
mapping 12 (SPM12, Wellcome Trust Centre for Neuro-
imaging, https ://www.fil.ion.ucl.ac.uk/spm) as imple-
mented in the PMOD software. For analysis of  [18F]FDG 
PET recordings, we calculated standardized uptake val-
ues (SUVs) for the baseline scans  (SUVpre) and MK-801 
challenge scans  (SUVpost) using the formula: SUV = tis-
sue activity concentration × body weight/injected radi-
otracer dose. We calculated mean SUVs in the striatum, 
cortex, hippocampus, thalamus, cerebellum, and whole 
brain [29, 30] using regions defined by the mouse 
region-of-interest (ROI) template [28]. We next calcu-
lated the percent change of SUV with the administra-
tion of MK-801 in the mGluR5 KO and WT mouse 
groups as follows: �SUV(%) = SUVpost−SUVpreSUVpre × 100.
Magnetic resonance spectroscopy
The MRS experiment was performed at Seoul National 
University College of Medicine approximately two weeks 
before the PET experiments. For MR data acquisition, 
mice were anesthetized with isoflurane (1.5% in oxygen) 
and placed inside the magnet in the prone position. The 
respiration rate and body temperature of the animals 
were monitored during the MR scan. All MR data were 
collected on a 9.4T animal MR scanner with a single-
channel surface coil for RF transmission and signal recep-
tion (Agilent Technologies, Santa Clara, CA, USA). For 
voxel localization, scout images were acquired along the 
axial, coronal, and sagittal directions using a T2-weighted 
fast spin echo sequence (repetition time (TR)/echo time 
(TE) = 3000/33  ms, echo train length = 4, field of view 
(FOV) = 20 × 20  mm2, matrix size = 256 × 256, slice 
thickness = 1  mm, 15 slices for the axial and sagittal 
directions and 10 slices for the coronal direction (no gap), 
receiver bandwidth (BW) = 100 kHz, and number of sig-
nal averages (NSA) = 2). Based on the scout images, spec-
troscopy voxels were positioned in the prefrontal cortex 
(1.5 × 1.5 × 3.0  mm3) and hippocampus (1.5 × 2.0 × 2.5 
 mm3). Then, the first- and second-order auto-shimming 
was performed followed by manual refinement.
1H-MRS data were acquired with a spin echo, full-
intensity acquired localized (SPECIAL) sequence 
[31]. To minimize voxel displacement, the carrier fre-
quency was adjusted by − 2.3 ppm from the water reso-
nance. A variable pulse power and optimized relaxation 
delays (VAPOR) [32] module combined with outer vol-
ume suppression (OVS) modules [33] preceded the 
SPECIAL sequence except for the acquisition of the 
double inversion recovery (DIR)-based metabolite-
nulled spectra. Other sequence parameters were: TR/
TE = 4000/2.84 ms, number of data points = 2048, spec-
tral BW = 5  kHz, 32-step phase cycling, and 2 dummy 
scans. A total of 12 spectra each with NSA = 64 were con-
secutively acquired for each voxel. A metabolite-nulled 
spectrum was acquired for each voxel as a surrogate of 
spectral baseline [34] using a DIR-SPECIAL sequence 
(TR/TE = 4650/2.84  ms, NSA = 320, and 1st/2nd inver-
sion time (TI) = 2150/686 ms).
The spectral basis set for metabolites was simulated 
using GAMMA [35] in response to a single spin echo 
sequence for metabolites, according to the reported 
chemical shifts and J-coupling constants [36]. Data were 
zero-filled to 4096 points, apodized, and phase-corrected 
by using jMRUI [37]. The residual water signal was 
removed by the HLSVD filter [38]. The individual metab-
olites were quantified from the spectra using AMARES 
[39]. The metabolite-nulled spectrum was also incorpo-
rated into the spectral basis set [34]. Only the glutamate 
data with a Cramer–Rao lower bound (CRLB) of ≤ 30% 
were included in the statistical analysis.
Statistical analysis
Between-group comparisons of  [18F]FDG PET SUVs 
were performed using a linear mixed model. The mouse 
group and brain ROIs were treated as fixed effects and 
brain regions were also treated as random effects, while 
 SUVpre,  SUVpost and ΔSUV were treated as depend-
ent variables. We additionally applied the multivariate 
approach using a repeated measures analysis of vari-
ance (ANOVA) of the SUV with time (pre- versus post-
MK-801) as a within-subjects factor and group (mGluR5 
KO versus WT) as a between-subjects factor, to account 
for interaction effects of MK-801 treatment and geno-
type. Given the small sample size, pairwise comparisons 
between  SUVpre and  SUVpost were also performed using 
the Wilcoxon rank test. Between-group comparisons 
of glutamate levels were performed using the Mann–
Whitney U test. Correlation analyses between baseline 
regional (prefrontal cortex and hippocampus) glutamate 
levels and  SUVpre were performed in a multimodal PET-
MRS approach. To compare between-group differences 
of the correlation coefficients, Fisher’s Z-transformation 
analysis was conducted. The significance level was set at 
p < 0.05 for all statistical analyses. All statistical analyses 
were performed using R software (version 3.5.1, R Foun-
dation for Statistical Computing, Vienna, Austria).
Results
The demographic characteristics of the mGluR5 KO and 
WT mice are presented in Table  1. Between-group dif-
ferences of age, sex, weight, and injected  [18F]FDG dose 
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were not significant (Table  1). The  SUVpre and  SUVpost 
are shown in Fig. 1a, and the ΔSUV is shown in Fig. 1b 
for the six ROIs (Fig. 1).
Between‑group comparisons
The linear mixed model analysis of ΔSUV as the 
dependent variable showed a significant main effect 
of group [F(1,19) = 6.62, p = 0.019], and the linear 
mixed model analysis of  SUVpost as the dependent 
variable also showed a significant main effect of group 
[F(1,19) = 7.08, p = 0.015]. However, the analysis of 
 SUVpre as the dependent variable showed no signifi-
cant main effect of group [F(1,19) = 0.05, p = 0.827]. 
The Bonferroni post hoc analysis revealed significantly 
lower  SUVpost and ΔSUV in all ROIs in the mGluR5 
KO mice compared to WT mice (p < 0.05), whereas 
there were no significant between-group differences 
in  SUVpre in any ROI (p > 0.1) (Fig.  1, Table  2). The 
repeated measures ANOVA also showed a significant 
MK-801 treatment x genotype interaction effect for all 
ROIs [cortex: F(1,19) = 5.91, p = 0.039; hippocampus: 
F(1, 19) = 4.79, p = 0.041; thalamus: F(1, 19) = 4.68, 
p = 0.043; striatum: F(1, 19) = 4.45, p = 0.048, cer-
ebellum: F(1, 19) = 4.42, p = 0.049; whole brain: F(1, 
19) = 4.90, p = 0.039]. Additional pairwise compari-
sons using the Wilcoxon rank test showed significantly 
decreased SUVs after administration of MK-801 in all 
ROIs in the mGluR5 KO mice (p < 0.05), except for the 
striatum (p = 0.054), but no significant changes of SUVs 
in WT mice (p > 0.1) (Table 3). Among the 11 mGluR5 
KO mice, the glutamate levels were available in the pre-
frontal cortex of nine mice and the hippocampus of ten 
mice, while MRS for glutamate was successful in all 
WT mice in both regions. Between-group comparisons 
using the Mann–Whitney U test showed no significant 
differences in glutamate levels (p > 0.1) (Table 4).
Table 1 Demographic characteristics and scan parameters
KO knockout, WT wild type, SD standard deviation
† Odds ratio
Variables Mouse type t-value p‑value
mGluR5 KO (n = 11)
Mean ± SD
WT (n = 10)
Mean ± SD
Age (day) 252.6 ± 68.5 222.4 ± 45.9 1.66 0.10
Male/female 8/3 5/5 0.39† 0.39
Weight (g) 22.9 ± 4.2 24.0 ± 3.5 − 0.93 0.36
[18F] FDG 
injected 
dose (MBq)
4.1 ± 0.6 4.3 ± 0.6 − 1.02 0.32
[18F] FDG 
injected 
dose/
weight 
(MBq/g)
0.18 ± 0.37 0.18 ± 0.32 0.20 0.84
Fig. 1 The mean  [18F]FDG PET SUV and ΔSUV with standard error bars in mGluR5 KO and WT mice. a Significantly decreased SUVs were observed 
in mGluR5 KO mice after the acute administration of MK‑801 (p < 0.05), whereas no significant alterations were observed in WT mice (p > 0.05). b 
The ΔSUV values were significantly different between mGluR5 KO and WT mice in ROIs (p < 0.05). SUV, standardized uptake value; ΔSUV, the percent 
change of SUV; ROI, region of interest
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Correlation analyses
The correlation analysis showed significant negative cor-
relations between baseline glutamate levels in the pre-
frontal cortex and  SUVpre in the six ROIs in mGluR5 
KO mice: cortex (rho = − 0.83, p = 0.005), striatum 
(rho = − 0.90, p = 0.001), hippocampus (rho = − 0.75, 
p = 0.020), thalamus (rho = − 0.68, p = 0.042), cerebellum 
(rho = − 0.73, p = 0.025), and whole brain (rho = − 0.82, 
p = 0.007) (Table 5, Fig.  2). However, there were no sig-
nificant correlations between prefrontal glutamate levels 
and  SUVpre in WT mice (p > 0.1) (Table  5, Fig.  2). The 
Fisher’s Z-transformation analysis revealed significant 
between-group differences of correlation coefficients 
between glutamate levels in the prefrontal cortex and 
 SUVpre in the three ROIs as follows: cortex (z = − 2.30, 
p = 0.022), striatum (z = − 2.77, p = 0.006), and whole 
brain (z = − 2.01, p = 0.045) (Table 5, Fig. 2). There were 
no significant correlations between baseline hippocampal 
glutamate levels and  SUVpre in either mGluR5 KO or WT 
mice (p > 0.1) (Table 5).
Table 2 Between-group comparisons of  [18F]FDG PET  SUVpre,  SUVpost and ΔSUV with acute MK-801 challenge
SUV standardized brain uptake value for  [18F]FDG, ΔSUV the percent change of SUV, SD standard deviation, KO knockout, WT wild type, CTX cortex, HIP hippocampus, 
THA thalamus, STR striatum, CB cerebellum, WB whole brain
* p < 0.05, **p < 0.01
Region Group SUVpre
Mean ± SD
t p‑value SUVpost
Mean ± SD
t p‑value ΔSUV (%) Mean ± SD t p‑value
CTX mGluR5 KO 2.04 ± 0.33 0.00 0.998 1.49 ± 0.42 − 3.00 0.007** − 24.0 ± 29.5 − 2.64 0.016*
WT 2.04 ± 0.68 2.16 ± 0.58 12.8 ± 31.8
HIP mGluR5 KO 1.90 ± 0.29 0.11 0.912 1.39 ± 0.40 − 2.40 0.027* − 23.6 ± 29.4 − 2.49 0.022*
WT 1.87 ± 0.63 1.93 ± 0.51 11.1 ± 34.2
THA mGluR5 KO 2.20 ± 0.34 0.22 0.825 1.57 ± 0.43 − 2.60 0.018* − 25.9 ± 28.1 − 2.64 0.016*
WT 2.15 ± 0.83 2.15 ± 0.60 11.0 ± 39.4
STR mGluR5 KO 2.10 ± 0.33 − 0.05 0.961 1.66 ± 0.47 − 2.81 0.011* − 17.5 ± 32.4 − 2.30 0.033*
WT 2.11 ± 0.67 2.29 ± 0.61 14.7 ± 30.4
CB mGluR5 KO 2.32 ± 0.39 0.47 0.643 1.53 ± 0.49 − 2.54 0.020* − 30.1 ± 33.0 − 2.37 0.028*
WT 2.21 ± 0.79 2.10 ± 0.56 3.0 ± 30.9
WB mGluR5 KO 2.00 ± 0.31 0.20 0.845 1.44 ± 0.37 − 2.79 0.011* − 25.4 ± 27.6 − 2.65 0.016*
WT 1.96 ± 0.66 1.99 ± 0.53 9.3 ± 32.4
Table 3 Wilcoxon rank test results for  pairwise 
comparisons in mGluR5 KO and WT mice
KO knockout, WT wild type, SUV standardized uptake value, SD standard 
deviation, CTX cortex, HIP hippocampus, THA thalamus, STR striatum, CB 
cerebellum, WB whole brain
* p < 0.05, **p < 0.01
Group Region SUVpre
Mean ± SD
SUVpost
Mean ± SD
W p value
mGluR5 KO CTX 2.04 ± 0.33 1.49 ± 0.42 8 0.024*
HIP 1.90 ± 0.29 1.39 ± 0.40 8 0.024*
THA 2.20 ± 0.34 1.57 ± 0.43 6 0.014*
STR 2.10 ± 0.33 1.66 ± 0.47 11 0.054
CB 2.32 ± 0.39 1.53 ± 0.49 5 0.010**
WB 2.00 ± 0.31 1.44 ± 0.37 6 0.014*
WT CTX 2.04 ± 0.68 2.16 ± 0.58 38 0.322
HIP 1.87 ± 0.63 1.93 ± 0.51 37 0.375
THA 2.15 ± 0.83 2.15 ± 0.60 30 0.846
STR 2.11 ± 0.67 2.29 ± 0.61 41 0.193
CB 2.21 ± 0.79 2.10 ± 0.56 29 0.922
WB 1.96 ± 0.66 1.99 ± 0.53 34 0.557
Table 4 Between-group comparisons of glutamate levels measured using magnetic resonance spectroscopy
KO knockout, WT wild type, PFC prefrontal cortex, HIP hippocampus
Region Group Mean ± SD W p value Effect size
Glutamate HIP mGluR5 KO 0.70 ± 0.11 58 0.579 0.135
WT 0.69 ± 0.13
PFC mGluR5 KO 1.02 ± 0.17 37 0.549 0.150
WT 1.14 ± 0.42
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Discussion
We examined the effects of mGluR5 genetic deletion 
on cerebral glucose metabolism measured with  [18F]
FDG PET and glutamate levels measured using MRS in 
living mice. While glutamate levels were measured only 
at baseline, we measured  [18F]FDG PET uptake before 
and after acute administration of the potent NMDA 
antagonist MK-801, aiming to probe the interaction 
Table 5 Correlation coefficients between  cortical glutamate levels and  baseline  [18F]FDG PET results  (SUVpre) 
with Fisher’s Z-transformation
SUV standardized uptake value, KO knockout, WT wild type, PFC prefrontal cortex, CTX cortex, HIP hippocampus, THA thalamus, STR striatum, CB cerebellum, WB whole 
brain
* p < 0.05, **p < 0.01, ***p < 0.001
MRS region PET region mGluR5 KO WT Fisher’s Z p value
n Rho p value n Rho p value
PFC CTX 9 − 0.83 0.005** 10 0.08 0.829 − 2.30 0.022*
HIP 9 − 0.75 0.020* 10 0.02 0.960 − 1.78 0.075
THA 9 − 0.68 0.042* 10 − 0.03 0.934 − 1.45 0.148
STR 9 − 0.90 0.001*** 10 0.07 0.855 − 2.77 0.006**
CB 9 − 0.73 0.025* 10 0.05 0.881 − 1.78 0.075
WB 9 − 0.82 0.007** 10 − 0.03 0.934 − 2.01 0.045*
HIP CTX 10 0.09 0.803 10 0.09 0.803 0.00 1.000
HIP 10 0.19 0.603 10 0.18 0.627 0.02 0.982
THA 10 0.05 0.881 10 0.24 0.511 − 0.35 0.729
STR 10 0.27 0.446 10 0.04 0.907 0.45 0.656
CB 10 0.13 0.726 10 0.15 0.676 − 0.05 0.962
WB 10 0.03 0.934 10 0.24 0.511 − 0.51 0.613
Fig. 2 Correlation analysis results between prefrontal glutamate levels to MRS and the baseline  [18F]FDG PET results  (SUVpre) in ROIs. There 
were significant negative correlations in mGluR5 KO mice (p < 0.05) (a), while no significant correlations were observed in WT mice (b). Fisher’s 
Z‑transformation showed significant between‑group differences of correlation coefficients in the cortex (z = − 2.30 p = 0.022), striatum (z = − 2.77 
p = 0.006), and whole brain (z = − 2.01 p = 0.045). SUV, standardized uptake value; ROI, region of interest
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between mGluR5 and NMDA receptors by regarding 
cerebral glucose metabolism as a proxy for net neuronal 
activity. At baseline, there were no significant group dif-
ferences in brain glucose metabolism between mGluR5 
KO and WT mice. However, we observed significantly 
lower glucose metabolism in the MK-801 challenge con-
dition relative to baseline in the mGluR5 KO mice. There 
were significant negative correlations between prefron-
tal glutamate levels and regional glucose metabolism in 
mGluR5 KO mice, but no such correlations in WT mice, 
nor did glutamate levels differ between the mGluR5 
KO and WT mice at baseline. Thus, treatment with the 
NMDA antagonist perturbed cerebral  [18F]FDG uptake 
only in the mGluR5 KO mice. This observation of an 
interaction between mGluR5 genetic deletion and acute 
MK-801 administration resulting in net global hypome-
tabolism seems to be in line with the reported reciprocal 
potentiation between glutamate signaling at mGluR5 and 
NMDA receptors [20, 21].
In our study, there was no statistically significant 
effect of acute MK-801 treatment on cerebral  [18F]FDG 
uptake in WT mice. A subanesthetic dose of the NMDA 
antagonist ketamine increased  [18F]FDG uptake in some 
rat brain regions [40]. Similarly, previous rodent stud-
ies reported focal increases in  [18F]FDG trapping in ret-
rosplenial and posterior cingulate cortices after a single 
dose of MK-801 (0.4 mk/kg) [41] and decreased  [18F]FDG 
uptake after one week of daily MK-801 administration 
(0.3 mg/kg) [42]. Our finding of a trend toward a global 
10% increase in  [18F]FDG uptake (Fig.  1) in the WT 
group was obscured by the high relative standard devia-
tion in the baseline evaluation of SUV. However, sample 
size calculation for our finding of a 10% increase in SUV 
with a 15% relative standard deviation predicts that we 
would have needed much larger populations of mice to 
avoid a type II statistical error.
Previous microdialysis studies showed that MK-801 
treatment acutely increases extraneuronal glutamate 
levels in rodent brain [43–45], which has been attrib-
uted to a net disinhibition of glutamate release via block-
ade of excitatory inputs to gamma-aminobutyric acid 
(GABA)-ergic interneurons in the cerebral cortex [46, 
47]. The present lack of significant effect of MK-801 on 
cerebral  [18F]FDG uptake in WT mice suggests that any 
stimulation of glucose consumption via increased acti-
vation by endogenous glutamate at mGluR5 and other 
non-NDMA sites may normally be roughly balanced by 
a reduced drive of neuronal activity arising from acute 
blockade of the NMDA sites. However, this putative bal-
ance was absent in the mGluR5 KO mice after MK-801 
challenge, where we observed a global and highly signifi-
cant 25% reduction in  [18F]FDG uptake relative to base-
line. Assuming the MK-801 treatment indeed increased 
glutamate release, we suppose that absent mGluR5 sign-
aling resulted in failure to accommodate for the reduced 
metabolic drive from the blocked NMDA receptors. We 
suppose that these results have some relevance for exci-
totoxicity of glutamate in the context of “Olney’s lesion,” 
which refers to neurovacuolation and mitochondrial 
damage confined to the posterior cingulate and retro-
splenial cortices of rats treated with MK-801 and other 
NMDA antagonists [48]. Interestingly, these are the same 
regions showing hypermetabolism on  [18F]FDG PET 
in the acute MK-801 rat study by Shirakawa et  al. [41] 
cited above. The present findings thus suggest a testable 
hypothesis that mGluR5 KO mice should be protected 
from Olney’s lesion, by virtue of the attenuation of global 
neuronal activity seen with  [18F]FDG PET.
In the MRS arm of the study, we observed no signifi-
cant differences in baseline prefrontal and hippocampal 
glutamate levels between the WT and mGluR5 KO mice, 
nor did we see any relationship between individual glu-
tamate levels and regional  [18F]FDG SUVs in the WT 
animals. However, there were significant inverse corre-
lations between glutamate levels in the prefrontal cortex 
and regional  [18F]FDG uptake in the mGluR5 KO mice. 
This might imply that mGluR5 KO unmasks a coupling 
between brain glutamate levels in the prefrontal cortex 
and global neuronal activity, which is normally obscured 
in WT mice. We can only speculate how this might arise, 
but we note that AMP-activated protein kinase (AMPK) 
phosphorylation is suppressed in mice with genetic 
ablation of mGluR5 [49]. Given that AMPK is critically 
involved in the regulation of glycolysis and mitochondrial 
respiration in response to synaptic activity [50], its home-
ostatic regulation may be perturbed in mGluR5 KO mice, 
thus contributing to the emergence of the negative cor-
relation between prefrontal glutamate and regional  [18F]
FDG uptake. There is little precedent for this finding, as 
there seems to be no previous studies linking glutamate 
levels with  [18F]FDG uptake in rodent brain. One report 
in Alzheimer’s disease patients reported no correlation 
between the amplitude of the glutamate/glutamine peak 
and the globally normalized  [18F]FDG SUV [51]. Another 
such multimodal study in epilepsy patients showed a 
significant correlation between the glutamate signal and 
 [18F]FDG uptake in the cortex contralateral to the epi-
leptic focus [52]. Thus, there is a clear need for further 
investigation of these relationships in healthy and dis-
eased brain.
Accumulating evidence suggests that glutamatergic 
signaling, particularly via NMDA receptors, is altered 
in schizophrenia [53]. A recent postmortem brain study 
demonstrated a significant attenuation of mGluR5 sign-
aling in the prefrontal cortex from patients with schizo-
phrenia, which was associated with reduced NMDA 
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receptor phosphorylation, suggesting that disruption 
of reciprocal interaction between mGluR5 and NMDA 
signaling is integral to glutamatergic dysfunction in 
schizophrenia [54]. Our present results in mGluR5 KO 
mice revealed significantly perturbed brain glucose 
metabolism that emerged only upon administration of 
the NMDA antagonist, thus implying an interaction of 
the two types of glutamate receptor in regulating brain 
glucose metabolism. Along with previous reports that 
mGluR5 antagonists significantly potentiate MK-801-in-
duced neurocognitive deficits in rats that resemble the 
cognitive symptoms of schizophrenia [24, 55], our results 
suggest that the mGluR5s may have little independent 
effects on brain glucose metabolism other than those 
mediated by interaction with NMDA receptors. A very 
recent PET study reported that lower mGluR5 availabil-
ity in the left temporal cortex and caudate was associated 
with more severe negative symptoms and worse cogni-
tive performance in male patients with chronic schizo-
phrenia [56]. Given these clinical and preclinical results, 
it should prove important to assess the relationships 
between mGluR5 availability, glutamate levels, and  [18F]
FDG uptake in patients with schizophrenia.
We acknowledge some limitations of the present 
study. The relatively small sample size may have lim-
ited the statistical power to detect group differences 
in the baseline PET and MRS measurements. In WT 
mice, the relative standard deviation of the means of 
baseline SUVs and prefrontal glutamate levels exceeded 
those in mGluR5 KO mice. However, the variances are 
in the range of those in previous studies [57, 58]. In the 
MRS arm of the study, we measured only baseline glu-
tamate levels. An additional study arm to measure glu-
tamate levels after acute administration of MK-801 in 
mGluR5 KO and WT mice might have confirmed our 
interpretation that absent mGluR5 signaling results in 
failure to accommodate the reduced metabolic drive 
from blocked NMDA receptors, in spite of MK-801-in-
duced glutamate release. This additional study would 
also have clarified the possible coupling/decoupling 
of cortical glutamate levels and global neuronal activ-
ity in mGluR5 KO and WT mice. Given the reported 
association between dysregulation of the mGluR5/
NMDA system with the pathophysiology of schizophre-
nia, we measured glutamate levels only in the prefron-
tal cortex and hippocampus, the two cortical regions 
most critically implicated in the schizophrenia patho-
physiology [59]. Future studies may be needed to inves-
tigate whether glutamate levels are altered in other 
brain areas in mGluR5 KO mice. In addition, given 
the global nature of glutamatergic signaling, investiga-
tions of other regions including the striatum and thala-
mus would be necessary to assess the broader regional 
correlations between glutamate levels and  [18F]FDG 
uptake in mGluR5 KO and WT mice. Since we had 
no vehicle or placebo group to control for compari-
sons in our MK-801 challenge experiments, we cannot 
exclude the possibility of confounds such as differen-
tial responses to stress in mGluR5 KO and WT mice. 
Since we did not measure blood glucose levels, we can-
not exclude the possibility that treatment and genotype 
influenced plasma glucose levels, and thus  [18F]FDG 
uptake. However, the previous investigation of a tracer 
for detecting pancreatic β-cell mass did not show any 
effects of MK-801 treatment on glucose-stimulated 
insulin secretion, from which we infer that present 
results were not due to global effects of plasma glucose 
in mGluR5 KO [60, 61]. Moreover, the largest MK-
801-induced SUV decrease in the KO mice was in the 
cerebellum (ΔSUV: − 30.1%), whereas the smallest MK-
801-induced SUV increase in the WT mice occurred in 
the cerebellum (ΔSUV: 3.0%). This finding of regional 
differences in MK-801-induced changes in  [18F]FDG 
uptake also argues against peripheral effects.
In conclusion, this is the first report on cerebral glucose 
metabolism and glutamate levels in living mGluR5 KO 
mice and the first report on the association between glu-
cose metabolism and glutamate levels in living rodents. 
We observed no significant group differences in baseline 
 [18F]FDG PET measurements or MRS glutamate levels 
between WT and mGluR5 KO mice. However, there was 
a substantial decline in  [18F]FDG SUVs specifically in the 
mGluR5 KO mice after challenge with an NMDA antag-
onist, suggesting that mGluR5 transmission normally 
moderates the net effects of NMDA receptor antagonism 
on glucose metabolism, i.e., neuronal activity. We also 
found significant inverse correlations between prefron-
tal glutamate levels and  [18F]FDG uptake in widespread 
brain areas at baseline in the mGluR5 KO mice, suggest-
ing the unmasking of an inhibitory component of the 
glutamatergic regulation of neuronal energy metabolism. 
Our study also suggests that multimodal neuroimaging 
in combination with pharmacological challenge using 
the mGluR5 KO mouse model may help to elucidate the 
nature of mGluR5/NMDA receptor interactions in the 
control of cerebral metabolism, with implications for dis-
orders such as schizophrenia.
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